Table 5 Characteristics of included studies
| Author, year | Patients (n) | Injection site | Injection dose | Identification rate | Number of SLNs | Localization method |
|---|---|---|---|---|---|---|
| Liu,2019 [24] | 75 | Intradermally inject at 3,6,9,12 o’clock around the arela | 0.5ml x 4 |
94.67 % (71/75) | 116 | Skin marked |
| Li,2019 [23] | 453 | Intradermally inject at 3,6,9,12 o’clock around the arela | 0.6ml x 4 |
98.2 % (445/453) | 765 | Skin marked |
| Kenzo,2019 [22] | 75 | Intradermally and subdermally inject at 3,6,9,12 o’clock around the arela | 0.25ml x 8 |
100 % (100/100) | 92 | Skin marked |
| Zhong,2018 [19] | 126 | Intradermally inject at outer upper quadrant near the areola | 2ml |
100 % (126/126) | 164 | FNA |
| Xie,2015 [18] | 101 | Intradermally inject at outer upper quadrant near the areola | 1.5ml | 97.03 % (98/101) | 115 | Guidewire |
| Zhao,2018 [20] | 110 | Intradermally inject at the periareolar area |
0.4ml (One or two additional injections if failed) |
96.4 % (106/110) | 134 | Skin marked |